Page last updated: 2024-10-29

inositol niacinate and Non-alcoholic Fatty Liver Disease

inositol niacinate has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies

Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Research Excerpts

ExcerptRelevanceReference
"Inositol hexanicotinate (IHN) self-micelle solid dispersion (SD) with glycyrrhizic acid (GA) and arabic gum (AG) was prepared by mechanical ball milling process to improve the solubility, stability of amorphous state, and bioavailability of IHN, which enhanced the treatment of IHN on hyperlipidemia and nonalcoholic fatty liver disease (NAFLD)."1.62Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease. ( Dushkin, AV; Su, W; Sun, C; Xu, W; Yu, J; Zhang, Q; Zheng, L; Zhu, X, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zheng, L1
Sun, C1
Zhu, X1
Xu, W1
Yu, J1
Zhang, Q1
Dushkin, AV1
Su, W1

Other Studies

1 other study available for inositol niacinate and Non-alcoholic Fatty Liver Disease

ArticleYear
Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease.
    International journal of pharmaceutics, 2021, Jun-01, Volume: 602

    Topics: Administration, Oral; Animals; Biological Availability; Calorimetry, Differential Scanning; Drug Del

2021